Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2023-05-10 Regulatory Filings
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing the presentation of cost-effectiveness data for Gleolan-guided surgery at the ISPOR 2023 conference. It discusses study results, product information, and forward-looking statements but does not contain any financial statements, regulatory filings, or detailed financial reports. It is not an earnings release, annual report, or any formal regulatory filing. The content is informational and promotional, typical of a press release or investor communication but does not fit into any specific financial report category. Therefore, it best fits under Regulatory Filings (RNS) as a general regulatory announcement or miscellaneous filing that does not fit other categories.
2023-05-10 English
News release - English.pdf
Investor Presentation Classification · 90% confidence The document is a press release announcing Medexus Pharmaceuticals' participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference. It includes details about the event, presentation timing, and webcast availability. There is no substantive financial data, detailed financial results, or comprehensive report content. The document is short (4440 characters) and serves as an announcement of an upcoming investor presentation rather than the presentation itself or a financial report. Therefore, it fits best as an Investor Presentation (IP) announcement or related communication. However, since it is primarily an announcement of participation and presentation timing rather than the presentation content itself, it aligns most closely with the Investor Presentation (IP) category, which includes detailed presentations for investors focusing on financials, strategy, and market position, especially when the presentation is forthcoming or webcasted. Confidence is high given the clear context and content type.
2023-04-18 English
News release - English.pdf
Earnings Release Classification · 95% confidence The document is a press release announcing preliminary revenue estimates for fiscal year 2023 and Q4 2023, along with a business update including a board chair transition. It contains forward-looking statements and operational highlights but does not include detailed financial statements or comprehensive financial analysis. The document is not a full annual report (10-K) or interim report (IR), nor is it a regulatory filing or certification. It is a business update and earnings preview, which aligns best with an Earnings Release (ER) as it provides initial financial results highlights and business developments without full audited financials. FY 2023
2023-04-11 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a new license deal for a pharmaceutical product (topical terbinafine) by Medexus Pharmaceuticals. It discusses the commercial rights, expected market impact, and strategic fit of the product, but does not contain any financial statements, earnings data, or detailed financial analysis. There is no indication that this is a regulatory filing, annual or quarterly report, or any other formal financial document. The content is focused on a business update related to licensing and commercialization, which fits best under Capital/Financing Update (CAP) as it relates to a licensing deal and potential revenue growth. The document length is 5699 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2023-03-22 English
News release - English.pdf
Regulatory Filings
2023-03-08 English
News release - English.pdf
Regulatory Filings
2023-03-06 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.